Lipid-lowering agents constitute a cornerstone of cardiovascular disease prevention. As such, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are among the most widely prescribed drugs worldwide, and statin therapy was shown to attenuate the risk of major vascular events, including myocardial infarctions, strokes, and coronary revascularization procedures, by about one-quarter for each 1 mmol/L per year reduction in low-density lipoprotein cholesterol. Despite the overwhelming evidence supporting the use of statins for cardiovascular disease prevention, conflicting findings have emerged from studies assessing the association between statin therapy and the risk of cognitive impairment, fueling a controversy that has been ongoing for more than two decades.
Link to full text.